Liver Fibrosis Scores and Coronary Artery Disease: Novel Findings in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease

References

• Sung KC, Yoo TK, Lee MY, Byrne CD, Zheng MH, Targher G. Comparative associations of nonalcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease with coronary artery calcification: a cross-sectional and longitudinal cohort study. Arterioscler Thromb Vasc Biol. 2023;43(3):482–491. doi:10.1161/ATVBAHA.122.318661
   PubMed Web of Science ®Google Scholar
• Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20. doi:10.1038/nrgastro.2017.109
   PubMed Web of Science ®Google Scholar
• Chan KE, Koh T, Tang A, et al. Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: a meta-analysis and systematic review of 10 739 607 individuals. J Clin Endocrinol Metab. 2022;107(9):2691–2700. doi:10.1210/clinem/dgac321
   PubMed Web of Science ®Google Scholar
• Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209. doi:10.1016/j.jhep.2020.03.039
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–357. doi:10.1002/hep.29367
   PubMed Web of Science ®Google Scholar
• Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999–2014.e1. doi:10.1053/j.gastro.2019.11.312
   PubMed Web of Science ®Google Scholar
• Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69(9):1691–1705. doi:10.1136/gutjnl-2020-320622
   PubMed Web of Science ®Google Scholar
• Duell PB, Welty FK, Miller M, et al. Nonalcoholic fatty liver disease and cardiovascular risk: a Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(6):e168–e185. doi:10.1161/ATV.0000000000000153
   PubMed Web of Science ®Google Scholar
• Mantovani A, Csermely A, Petracca G, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(11):903–913. doi:10.1016/S2468-1253(21)00308-3
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Cuevas J, Santos A, Armendariz-Borunda J. Pathophysiological molecular mechanisms of obesity: a link between MAFLD and NASH with cardiovascular diseases. Int J Mol Sci. 2021;22(21):11629. doi:10.3390/ijms222111629
   PubMed Web of Science ®Google Scholar
• Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846–854. doi:10.1002/hep.21496
   PubMed Web of Science ®Google Scholar
• Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317–1325. doi:10.1002/hep.21178
   PubMed Web of Science ®Google Scholar
• Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518–526. doi:10.1053/jhep.2003.50346
   PubMed Web of Science ®Google Scholar
• Jin JL, Zhang HW, Cao YX, et al. Liver fibrosis scores and coronary atherosclerosis: novel findings in patients with stable coronary artery disease. Hepatol Int. 2021;15(2):413–423. doi:10.1007/s12072-021-10167-w
   PubMed Web of Science ®Google Scholar
• Park HE, Kwak MS, Kim D, Kim MK, Cha MJ, Choi SY. Nonalcoholic fatty liver disease is associated with coronary artery calcification development: a longitudinal study. J Clin Endocrinol Metab. 2016;101(8):3134–3143. doi:10.1210/jc.2016-1525
   PubMed Web of Science ®Google Scholar
• Chen Q, Li Q, Li D, et al. Association between liver fibrosis scores and the risk of mortality among patients with coronary artery disease. Atherosclerosis. 2020;299:45–52. doi:10.1016/j.atherosclerosis.2020.03.010
   PubMed Web of Science ®Google Scholar
• Tokushige K, Ikejima K, Ono M, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. J Gastroenterol. 2021;56(11):951–963. doi:10.1007/s00535-021-01796-x
   PubMed Web of Science ®Google Scholar
• Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15(4):827–832. doi:10.1016/0735-1097(90)90282-T
   PubMed Web of Science ®Google Scholar
• Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 Suppl):S47–64. doi:10.1016/j.jhep.2014.12.012
   PubMed Web of Science ®Google Scholar
• Bonora E, Targher G. Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. Nat Rev Gastroenterol Hepatol. 2012;9(7):372–381. doi:10.1038/nrgastro.2012.79
   PubMed Web of Science ®Google Scholar
• Targher G, Bertolini L, Padovani R, et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care. 2006;29(6):1325–1330. doi:10.2337/dc06-0135
   PubMed Web of Science ®Google Scholar
• Shang Y, Nasr P, Widman L, Hagström H. Risk of cardiovascular disease and loss in life expectancy in NAFLD. Hepatology. 2022;76(5):1495–1505. doi:10.1002/hep.32519
   PubMed Web of Science ®Google Scholar
• Alon L, Corica B, Raparelli V, et al. Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Prev Cardiol. 2022;29(6):938–946.
   PubMed Web of Science ®Google Scholar
• Vanhoutte PM. Endothelial dysfunction: the first step toward coronary arteriosclerosis. Circ J. 2009;73(4):595–601. doi:10.1253/circj.CJ-08-1169
   PubMed Web of Science ®Google Scholar
• Federico A, Dallio M, Masarone M, Persico M, Loguercio C. The epidemiology of non-alcoholic fatty liver disease and its connection with cardiovascular disease: role of endothelial dysfunction. Eur Rev Med Pharmacol Sci. 2016;20(22):4731–4741.
   PubMed Web of Science ®Google Scholar
• Francque SM, van der Graaff D, Kwanten WJ. Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications. J Hepatol. 2016;65(2):425–443. doi:10.1016/j.jhep.2016.04.005
   PubMed Web of Science ®Google Scholar
• Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363(14):1341–1350. doi:10.1056/NEJMra0912063
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology. 2010;52(2):774–788. doi:10.1002/hep.23719
   PubMed Web of Science ®Google Scholar
• Katakami N. Mechanism of development of atherosclerosis and cardiovascular disease in diabetes mellitus. J Atheroscler Thromb. 2018;25(1):27–39. doi:10.5551/jat.RV17014
   PubMed Web of Science ®Google Scholar
• Song DS, Chang UI, Kang SG, Song SW, Yang JM. Noninvasive serum fibrosis markers are associated with coronary artery calcification in patients with nonalcoholic fatty liver disease. Gut Liver. 2019;13(6):658–668. doi:10.5009/gnl18439
   PubMed Web of Science ®Google Scholar
• Ismaiel A, Dumitraşcu DL. Cardiovascular risk in fatty liver disease: the liver-heart axis-literature review. Front Med (Lausanne). 2019;6:202. doi:10.3389/fmed.2019.00202
   PubMed Web of Science ®Google Scholar
• Turan Y. The nonalcoholic fatty liver disease fibrosis score is related to epicardial fat thickness and complexity of coronary artery disease. Angiology. 2020;71(1):77–82. doi:10.1177/0003319719844933
   PubMed Web of Science ®Google Scholar
• Puchner SB, Lu MT, Mayrhofer T, et al. High-risk coronary plaque at coronary CT angiography is associated with nonalcoholic fatty liver disease, independent of coronary plaque and stenosis burden: results from the ROMICAT II trial. Radiology. 2015;274(3):693–701. doi:10.1148/radiol.14140933
   PubMed Web of Science ®Google Scholar
• Liu HH, Cao YX, Jin JL, et al. Liver fibrosis scoring systems as novel tools for predicting cardiovascular outcomes in patients following elective percutaneous coronary intervention. J Am Heart Assoc. 2021;10(3):e018869. doi:10.1161/JAHA.120.018869
   PubMed Web of Science ®Google Scholar
• Wang C, Cai Z, Deng X, et al. Association of hepatic steatosis index and fatty liver index with carotid atherosclerosis in type 2 diabetes. Int J Med Sci. 2021;18(14):3280–3289. doi:10.7150/ijms.62010
   PubMed Web of Science ®Google Scholar
• Mangla N, Ajmera VH, Caussy C, et al. Liver stiffness severity is associated with increased cardiovascular risk in patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2020;18(3):744–746.e1. doi:10.1016/j.cgh.2019.05.003
   PubMed Web of Science ®Google Scholar
• Lee J, Kim HS, Cho YK, et al. Association between noninvasive assessment of liver fibrosis and coronary artery calcification progression in patients with nonalcoholic fatty liver disease. Sci Rep. 2020;10(1):18323. doi:10.1038/s41598-020-75266-4
   PubMed Web of Science ®Google Scholar
• Maeda D, Kanzaki Y, Sakane K, et al. Prognostic value of the liver fibrosis marker fibrosis-5 index in patients with acute heart failure. ESC Heart Fail. 2022;9(2):1380–1387. doi:10.1002/ehf2.13829
   PubMed Web of Science ®Google Scholar
• Kramer CK, Zinman B, Gross JL, et al. Coronary artery calcium score prediction of all cause mortality and cardiovascular events in people with type 2 diabetes: systematic review and meta-analysis. BMJ. 2013;346:f1654. doi:10.1136/bmj.f1654
   PubMedGoogle Scholar
• Otton JM, Yu CY, McCrohon J, Sammel N, Feneley M. Accuracy and clinical outcomes of computed tomography coronary angiography in the presence of a high coronary calcium score. Heart Lung Circ. 2013;22(12):980–986. doi:10.1016/j.hlc.2013.05.647
   PubMed Web of Science ®Google Scholar
• Gofton C, Upendran Y, Zheng MH, George J. MAFLD: how is it different from NAFLD. Clin Mol Hepatol. 2023;29(Suppl):S17–S31. doi:10.3350/cmh.2022.0367
   PubMedGoogle Scholar
• Chun HS, Lee M, Lee JS, et al. Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease. Liver Int. 2023;43(3):608–625. doi:10.1111/liv.15508
   PubMed Web of Science ®Google Scholar
• Kim H, Lee CJ, Ahn SH, et al. MAFLD predicts the risk of cardiovascular disease better than NAFLD in asymptomatic subjects with health check-ups. Dig Dis Sci. 2022;67(10):4919–4928. doi:10.1007/s10620-022-07508-6
   PubMed Web of Science ®Google Scholar
• Liu HH, Cao YX, Jin JL, et al. Metabolic-associated fatty liver disease and major adverse cardiac events in patients with chronic coronary syndrome: a matched case-control study. Hepatol Int. 2021;15(6):1337–1346. doi:10.1007/s12072-021-10252-0
   PubMed Web of Science ®Google Scholar
• Lee H, Lim TS, Kim SU, Kim HC. Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population. Hepatol Int. 2022;16(6):1308–1317. doi:10.1007/s12072-022-10407-7
   PubMed Web of Science ®Google Scholar
• Chen X, Chen Z, Jiang L, Huang J, Zhu Y, Lin S. MAFLD is associated with increased all-cause mortality in low cardiovascular-risk individuals but not in intermediate to high-risk individuals. Nutr Metab Cardiovasc Dis. 2023;33(2):376–384. doi:10.1016/j.numecd.2022.11.007
   PubMed Web of Science ®Google Scholar